|
Orthotopic Tumor Models
ProQinase offers orthotopic and metastasizing in vivo tumor models in mice.
| Tissue Origin |
Tumor Cell Line |
Species |
| Blood/Leukemia |
Molm-13 |
Human |
| MV4-11 |
Human |
| Kidney |
RENCA |
Mouse |
| Liver |
Alexander* |
Human |
| Pancreas |
AsPC-1 |
Human |
| MIA PaCa-2 |
Human |
| Prostate |
PC-3 |
Human |
| LNCaP |
Human |
| Skin |
B16F10* |
Mouse |
*not yet available with bioluminescence imaging
back
Target-Specific Tumor Models with Genetically Engineered Cells
ProQinase offers target-specific tumor models in mice using cell lines, which were genetically engineered to control the expression of tumor-relevant proteins. Additional cell lines are in preparation, please inquire for detailed information.
| Target |
Tumor Cell Line |
Species |
| Aromatase |
MCF7 CA |
Human |
| IGF1 Receptor |
MEF IGF1Rrep |
Mouse |
| ERBB2 Receptor |
NIH3T3 ERBB2-Rrep |
Mouse |
back
Subcutaneous Xenograft Tumor Models
ProQinase offers xenograft models with several tumor cell lines that grow as subcutaneous tumors in mice. More cell lines of the NCI panel can easily be established, if they are tumorigenic in mice.
| Tissue Origin |
Tumor Cell Line |
Species |
Blood/Leukemia
|
Karpas-299
|
Human |
| Molm-13 |
Human |
| MV4-11 |
Human |
Brain
|
C6
|
Rat |
SK-N-MC
|
Human |
Breast
|
MCF7
|
Human |
MDA-MB-468
|
Human |
Cervix
|
HeLa
|
Human |
| Colon |
Colo 205 |
Human |
| HCT-116 |
Human |
HT29
|
Human |
LoVo
|
Human |
LS 174T
|
Human |
| RKO |
Human |
SW-620
|
Human |
| Gastric |
MKN-45 |
Human |
| Liver |
Alexander |
Human |
| Lung |
A549 |
Human |
| H69 |
Human |
| Calu-6 |
Human |
| Ovary |
SKOV-3 |
Human |
| Pancreas |
AsPC-1 |
Human |
MIA PaCa-2
|
Human |
| Prostate |
PC3 |
Human |
Skin
|
A375 |
Human |
| A431 |
Human |
| B16 |
Mouse |
back
Study Design and Readouts
The experimental design of any in vivo tumor study can be tailored to meet our customer's individual requirements. One can choose between dose finding and efficacy studies. Furthermore, the customer can decide on:
- Route of application: e.g. orally, s.c., i.m., i.p.
- Scheme of application: from once daily up to continuously
- Time schedule: e.g. therapy start, study duration
- Pretreatment period before inoculation of tumor cells
- Parameters monitored during the study: e.g. animal behavior, tumor size, blood parameters
In addition to standard readouts (animal weight, tumor weight, tumor volume, metastasis pattern) ProQinase offers the following readouts and technologies at study end:
- Blood parameters (e.g. soluble biomarker [VEGF, soluble VEGFR-2/KDR])
- Necropsy (collection of more than 40 tissues and organs)
- Immunohistochemistry (e.g. microvessel density, proliferation and apoptotic indices)
- Tumor imaging (ultrasound, in vivo bioluminescence imaging)
- Corrosion casts
Please inquire for a specific quote.
back
|
|